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Exome sequencing in pooled DNA 
samples to identify maternal pre-
eclampsia risk variants
Tea Kaartokallio1,*, Jingwen Wang2,*, Seppo Heinonen3, Eero Kajantie4,5,6, Katja Kivinen7, 
Anneli Pouta6,8, Paul Gerdhem9,10, Hong Jiao2, Juha Kere2,11,12 & Hannele Laivuori1,3,13
Pre-eclampsia is a common pregnancy disorder that is a major cause for maternal and perinatal 
mortality and morbidity. Variants predisposing to pre-eclampsia might be under negative evolutionary 
selection that is likely to keep their population frequencies low. We exome sequenced samples from 
a hundred Finnish pre-eclamptic women in pools of ten to screen for low-frequency, large-effect 
risk variants for pre-eclampsia. After filtering and additional genotyping steps, we selected 28 low-
frequency missense, nonsense and splice site variants that were enriched in the pre-eclampsia pools 
compared to reference data, and genotyped the variants in 1353 pre-eclamptic and 699 non-pre-
eclamptic women to test the association of them with pre-eclampsia and quantitative traits relevant 
for the disease. Genotypes from the SISu project (n = 6118 exome sequenced Finnish samples) were 
included in the binary trait association analysis as a population reference to increase statistical power. 
In these analyses, none of the variants tested reached genome-wide significance. In conclusion, the 
genetic risk for pre-eclampsia is likely complex even in a population isolate like Finland, and larger 
sample sizes will be necessary to detect risk variants.
Pre-eclampsia is a common and complex vascular pregnancy disorder. It is characterized by hypertension and 
proteinuria, and often involves impaired placental development1,2. The disease is a major cause for both maternal 
and perinatal mortality and morbidity3, and predicts increased risk of chronic cardiometabolic diseases later in 
life4,5.
Genetic factors contribute to pre-eclampsia susceptibility. Heritability estimates for pre-eclampsia range 
between 0.54 and 0.68, consisting of both maternal and fetal contribution6,7. Risk for pre-eclampsia is elevated 
after first pre-eclamptic pregnancy8, and in women with an affected first-degree relative9. Genome-wide linkage 
studies in pre-eclampsia families have revealed several susceptibility loci for the disease10–14. Also, numerous 
candidate gene studies (summarized in meta-analyses15–17), mostly assessing the effect of maternal genotype, 
and two relatively modestly sized genome-wide association studies on maternal pre-eclampsia risk have been 
published18,19. Despite these attempts to discover genetic risk variants for pre-eclampsia, no robustly replicated 
candidate genes have yet been identified.
Because pre-eclampsia is a major cause for both maternal and fetal mortality, preterm birth and fetal growth 
restriction3,20,21, it can be assumed to reduce reproductive success. Therefore, negative evolutionary selection 
likely maintains population frequencies of pre-eclampsia risk variants low. Following this reasoning, we focus 
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on screening for low-frequency (minor allele frequency (MAF) 1–5%) maternal variants with large or moderate 
effect on the risk of pre-eclampsia.
The population history of Finland is characterized by strong founder effect, periods of rapid population 
growth, and internal migrations and establishment of population isolates as late as in the 16th century (summa-
rized in refs 22,23). The Finnish population has therefore gone through multiple relatively recent bottlenecks, and 
evolutionary selection has not eliminated deleterious variants as effectively as in older and more outbred popu-
lations. This has led to enrichment of low-frequency loss-of-function variants24. Number of samples required to 
reach adequate statistical power to detect associations with some pathogenic variants might therefore be reduced 
in the Finnish population25, making it an ideal choice for studies concentrating on low-frequency variants.
Although the cost of next-generation sequencing has reduced considerably over the past years, costs for 
studies utilizing these methods still remain substantially high. Pooling DNA samples together can significantly 
decrease the cost of genome-wide sequencing, especially in the studies targeting rare or low-frequency variants26. 
Here we exploited this idea by pooling DNA from a hundred pre-eclamptic women in pools of ten, and by exome 
sequencing the pools to screen for pre-eclampsia risk variants.
Samples and Methods
Study participants. The sample set utilised in the exome sequencing included a hundred Finnish pre-ec-
lamptic women, pooled in pools of ten. Ninety of the study participants were selected from the Finnish Genetics 
of Pre-eclampsia Consortium (FINNPEC) case-control cohort that was collected from five Finnish university 
hospitals during 2008 to 201127. Ten participants belong to separate families chosen from the pre-eclampsia fam-
ily cohort recruited from the Kainuu and Helsinki regions10. All the FINNPEC cases included in the exome 
sequencing had severe pre-eclampsia. Two of the pools contained women with early-onset disease, three pools 
women with high proteinuria, one pool women with previous miscarriages, and one pool women with recurrent 
pre-eclampsia (Supplementary Table S1). Women with severe pre-eclampsia were prioritised in the sample selec-
tion as they are more likely to possess genetic risk factors for the disease. Clinical definitions as well as the sample 
collection and DNA extraction methods are described in Supplementary File 1.
The first individually Sequenom genotyped sample consisted of 180 pre-eclamptic and 180 healthy pregnant 
women, including the 100 pre-eclamptic cases originally exome sequenced, and additional study subjects from 
the FINNPEC cohort. The exclusion criteria for the controls were any pregnancy complication in the current 
pregnancy, pre-eclampsia in any pregnancy, chronic hypertension and pregestational diabetes mellitus.
The second individually genotyped sample set included 1353 pre-eclamptic and 699 non-pre-eclamptic 
women. These also include all the samples from the first Sequenom genotyping, all of which except the family 
samples were re-genotyped in the second run. All the women, except for the ten family cohort members, were 
selected from the FINNPEC cohort. The inclusion criterion for the cases was pre-eclampsia, and for the con-
trols non-pre-eclamptic pregnancy. The exclusion criteria for the controls were pre-eclampsia in any pregnancy, 
small-for-gestational age (SGA) infant or placental insufficiency, gestational hypertension, chronic hypertension 
and placental ablation.
All study participants have provided a written informed consent. The study protocols have been approved 
by the Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa, and the methods were 
carried out in accordance with the approved guidelines.
Variant data from a hundred Swedish scoliosis cases28 that were exome sequenced with a pooled strategy iden-
tical to ours were utilised in the exome sequencing variant filtering to omit false positive and common variants.
The Sequencing Initiative Suomi (SISu 3.0) data set was utilised in the Sequenom phase 2 association analysis 
as population specific reference data to increase the statistical power. The SISu database is available online (http://
www.sisuproject.fi/) and at the time of the analysis contained exome sequence data from over 6100 Finns. The 
data set was utilized as a reference unselected for the pre-eclampsia phenotype as this information was not avail-
able for the sequenced individuals.
A summary of the study participants is shown in Table 1.
Exome sequencing. Details of the exome sequencing are described in Supplementary File 1. The ini-
tial quality control of the sequencing data was performed by the sequencing service provider (Science for Life 
Laboratory, Stockholm, Sweden). The paired-end reads were aligned to the human reference genome hg19 with 
the Burrows-Wheeler Aligner (BWA) software package, version 0.6.129. SAMtools version 0.1.1830 was used to 
remove PCR duplicates in each pool, to filter out multiply mapped reads (mapping quality score < 20) and to 
call variants. The uniquely mapped reads were used as input for variant (SNV) calling for each pool with the 
Exome sequencing Association analysis
PE cases
Scoliosis reference 
for filtering* PE cases
Non-PE 
controls
SISu 
reference
Sample size 100 100 1353 699 6118
Female% 100% 76% 100% 100% 57%
Ancestry Finnish Swedish Finnish Finnish Finnish
Table 1.  Summary of the study participants utilised in the exome sequencing and in the association 
analysis. * Swedish scoliosis patients that were pooled and exome sequenced with the same method as the 
pre-eclamptic cases. These controls were utilised as a technical control to filter out false positive and common 
variants. PE = pre-eclampsia; SISu = Sequencing Initiative Suomi.
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SAMtools default setting, and the variants identified were merged together. Annotation was completed using the 
ANNOVAR software31 with dbSNP version 137 and the 1000 Genomes 2012 APR32. BEDtools, version 2.16.233 
was applied for evaluating read depth and coverage.
The following filtering criteria were applied to the variants called. The missense, nonsense and splice site 
variants that were present in at least two pre-eclampsia pools were considered further. Insertions and deletions 
were excluded from the analysis, because they could not be called reliably. Exome sequencing data from Swedish 
scoliosis patients were produced with a pooling strategy identical to ours and were utilised in the filtering as a 
technical control to exclude false positive and common variants. The variants present in over five scoliosis pools 
were excluded. The variants present in less than two scoliosis pools were filtered for European allele frequency 
in the 1000 Genomes data, and only the variants with MAF ≤ 0.05 were included. MAF of each variant in the 
exome-sequenced samples was estimated by calculating the proportion of reads carrying minor allele in the total 
amount of reads covering the position. The MAF estimation is based on an assumption that each sample is equally 
represented within a pool. The MAF estimates in the pre-eclampsia pools were compared to the MAFs in the 
reference data sets (SISu 2014, the 1000 Genomes European data APR2012 and the scoliosis exome sequencing 
data). By using three reference data sets we were able to obtain comprehensive picture of the variant frequencies 
in the Finnish and European populations, and also to estimate relevance of those variants that were absent in the 
population-specific reference data SISu. The variants with pre-eclampsia_MAF/reference_MAF ratio ≥ 1.5 in all 
the available comparisons were selected. In addition, five variants that were close to the cut-off or had high ratio 
in one or two of the comparisons were included. The following procedures were also utilised. Variation located 
in the genes listed in the papers by Fuentes Fajardo et al.34 and Ju et al.35 were excluded. These papers have listed 
genes that contain excess amount of variation, likely due to assembly errors in the reference sequence or align-
ment errors e.g. in highly polymorphic genomic regions. The variants flagged “suspected” in the dbSNP database 
were excluded. For the variants with no MAF information available in our default reference data sets, we utilised 
data from other sources (the 1000 Genomes ALL, CSAgilent), and excluded the variants with MAF higher than 
or similar to the MAF in our data. In addition to the main filtering strategy, we also focused on the linkage peak 
regions identified in the previous studies by our group10,36, and selected the linkage peak region variants that 
were present in the pool containing pre-eclampsia family samples, had the 1000 Genomes EUR MAF ≤ 0.05, 
and pre-eclampsia_MAF/reference_MAF≥ 1.5. We also looked for candidate variants among the SNPs whose 
reference allele was the minor allele. For this filtering strategy we selected the missense, nonsense and splice site 
variants with the 1000 Genomes European reference allele frequency ≤ 0.05, and pre-eclampsia_refAllele/SISu 
and pre-eclampsia_refAllele/scoliosis_refAllele ≥ 1.5, and selected the variants whose reference allele was present 
in ≤ 2 scoliosis pools and in over two pre-eclampsia pools.
Sequenom genotyping. Two rounds of Sequenom genotyping were performed. The purpose of the 
first round was to verify the presence and enrichment of the selected variants individually in the original 
exome-sequenced samples, whereas the second round was conducted to test the association of the variants with 
pre-eclampsia.
Of the 59 variants selected based on the exome sequencing, 46 were directly fitted to three Sequenom iplexes. 
In addition, two of the variants were captured through tagging SNPs. Rs117741116 tagged rs139702277 with 
r2 = 1 and D′ = 1 in the 1000 Genomes FIN and CEU populations, and rs12462506 tagged rs3745601 with 
r2 = 0.96 and D′ = 1 in the 1000 Genomes FIN population. The rest of the SNPs were left out, because of issues in 
assay design. In total, 48 variants were genotyped. The first, the second and the third iplexes contained 24, 17 and 
7 variants, respectively. For the second genotyping run, 28 variants were selected for genotyping in two iplexes. 
In addition, rs6025 in F5 was included to the panel to investigate if the previously found association between the 
variant and pre-eclampsia15–17 would be replicated in our data. The assay design and the genotyping were per-
formed with Sequenom MassArray system at the Institute for Molecular Medicine Finland FIMM Technology 
Centre, University of Helsinki. The Technology Centre performed routine quality control steps to ensure high 
quality of the genotyping.
Association analysis. Association of the variants with pre-eclampsia was evaluated by chi-square test in the 
PLINK software v1.0737. Genotypes from the Finnish SISu (3.0) data set containing 6118 individuals were com-
bined with our control data to increase the statistical power. Association test was conducted both in the FINNPEC 
case-control data set and in the merged FINNPEC – SISu data. Two X chromosomal variants were excluded from 
the latter analysis, because the SISu data contain also males. The allele frequencies of autosomal variants are not 
assumed to differ between females and males. Any Sequenom genotyped sample with failed genotyping for > 2 
variants that had been otherwise successfully genotyped was removed from the analysis. Hardy-Weinberg equi-
librium (HWE) was calculated independently for the Sequenom genotyped case-control samples, for the SISu 
data and for the merged FINNPEC-SISu data. Differential genotype missingness between the cases and controls 
was tested in the FINNPEC cohort.
A standard linear regression model in the PLINK software was applied for testing association of the genetic 
variants with quantitative traits relevant for pre-eclampsia in the FINNPEC cohort. The quantitative traits utilized 
in the association testing included the highest systolic blood pressure, the highest diastolic blood pressure, pro-
teinuria and relative birth weight of the baby. An additive model was applied in the analyses.
Statistical power was calculated with Genetic Power Calculator using the “case-control for discrete traits” 
module38 (http://pngu.mgh.harvard.edu/~purcell/gpc/cc2.html). With a pre-eclampsia prevalence of 0.05 and 
a risk allele frequency of 0.05, our cohort of 1353 pre-eclamptics and ~6800 controls (the non-pre-eclamptic 
FINNPEC controls and the SISu (3.0) data unselected for the pre-eclampsia phenotype combined), was estimated 
to be sufficient to detect an effect size of 1.65 for risk heterozygote and 3 for risk homozygote with power of 0.80 
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when α < 5 × 10−8. Under the aforementioned parameters, for the variants with a risk allele frequency of 0.01, we 
could detect effect sizes of 2.52 and 5 for the risk heterozygote and homozygote, respectively.
Results
Clinical characteristics. Clinical characteristics of the study participants are presented in Table 2. The 
pre-eclamptic women in both Sequenom sample sets delivered on average earlier and had babies with lower 
absolute and relative birth weight than the control women. In the second Sequenom genotyping sample set the 
number of primiparous women was larger and BMI higher among the pre-eclamptic women, and larger percent-
age of them was affected by pregestational or gestational diabetes.
Exome sequencing data. The sequencing provider delivered a total number of 299 to 482 million reads in 
each sample pool. Over 98% of the reads could be mapped to the reference genome hg19. Per pool on average, 
90% and 80% of the SureSelect target regions were covered by a depth of at least 30x and 60x, respectively, and the 
average depth of the target regions per pool was between 95x and 277x, the average of all pools being 220x. Eight 
of the ten pools had average coverage over 200x in the enrichment regions. The total number of variants called 
was 2,308,376. The main filtering strategy applied to these variants is illustrated in Fig. 1 and explained in detail 
in the Samples and Methods section. After excluding the variants with mapping quality < 20 or depth < 10x, there 
were 259,919 variants left, of which 31,579 were located in protein-coding regions. By applying the filtering steps, 
we identified 59 candidate variants that seemed to be enriched in the exome sequenced pre-eclamptic women 
(Supplementary Table S2).
The first round of Sequenom genotyping in the FINNPEC samples. The first round of Sequenom 
genotyping was carried out in a sample set of 180 cases and 180 controls including the 100 exome sequenced 
samples. The purpose of this step was to verify the presence of the variants in the original samples and the MAF 
difference between pre-eclamptic women and general population. All assays had a success rate > 95%. Of the 48 
variants that were genotyped, three were monomorphic. After excluding these variants, correlation coefficient 
between the MAF estimates from the exome sequencing and the MAFs obtained from the Sequenom genotyping 
for the exome sequenced samples was 0.94, showing that we were able to estimate MAFs in the exome sequencing 
fairly accurately. Four of the variants were not in HWE in the controls. Twenty-eight variants that had OR ≤ 0.65 
or ≥ 1.3 were selected for the second round of Sequenom genotyping in a larger case-control cohort. The results 
of the first Sequenom round are shown in Supplementary Table S3.
The second round of Sequenom genotyping in the FINNPEC samples. In the second round of gen-
otyping all the variants except failed rs6681 were successfully genotyped. After excluding 17 cases and 5 controls 
with more than 2 failed genotypes, the genotyping rate for the variants in the remaining individuals was over 96%. 
Concordance rate of the genotypes in the 350 individuals included in both Sequenom runs was 0.9992. Three 
individuals with at least one discordant genotype between the runs were excluded. Association of the variants 
Maternal or perinatal 
characteristics
Exome-sequencing Sequenom genotyping 1 Sequenom genotyping 2
Pre-eclampsia 
(n = 100)
Pre-eclampsia 
(n = 180) Control (n = 180) P
Pre-eclampsia 
(n = 1353) Control (n = 699) P
Age (years) 30 (27/32) 29 (26/32) 28 (25/32) 0.515 30 (26/34) [1352] 29 (26/33) 0.010
Primipara 89 (89.0) 166 (92.2) 162 (90.0) 0.459 999 (73.8) 379 (54.2) < 0.001
BMI (kg/m2) 22.7 (20.8/25.1) [94] 22.4 (20.4/25.2) [174] 22.8 (20.7/25.0) 0.685 24.0 (21.3/27.8) [1344] 23.0 (20.8/25.8) < 0.001
Highest systolic blood pressure 
(mmHg) 168 (161/181) 168 (160/179) 125 (118/133) < 0.001 165 (154/179) 125 (118/133) < 0.001
Highest diastolic blood 
pressure (mmHg) 111 (105/117) [99] 111 (106/116) [179] 83 (78/88) < 0.001 109 (104/116) [1352] 82 (78/87) < 0.001
Proteinuria (g/24 h) 4.5 (2.3/7.3) [97] 4.8 (2.7/7.2) [177] NA NA 3.1 (1.3/6.1) [1202] 0.9 (0.7/1.3) [6] NA
Birth weight (g) 2650 (2006/3172) 2628 (1943/3123) 3543 (3256/3909) < 0.001 2770 (2075/3300) 3630 (3312/3950) < 0.001
Relative birth weight (SD) − 1.29 (− 1.88/− 0.48) [99]
− 1.38 (− 1.95/− 0.52) 
[179] − 0.12 (− 0.68/0.55) < 0.001
− 1.13 (− 1.88/− 0.30) 
[1351]
0.02 (− 0.58/0.69) 
[698] < 0.001
Gestational age at birth 
(weeks) 37.4 (34.4/39.0) [99] 37.4 (34.6/38.9) [179] 40.6 (39.7/41.3) < 0.001 37.7 (35.1/39.1) [1352] 40.4 (39.4/41.3) < 0.001
Chronic hypertension 3 (3.0) [99] 3 (1.7) [179] 0 0.123 235 (17.4) [1352] 0 < 0.001
Pregestational diabetes 
mellitus 0 [99] 0 [179] 0 NA 40 (3.0) [1352] 5 (0.7) 0.001
Gestational diabetes mellitus 1 (1.0) [99] 1 (0.6) [179] 0 0.499 184 (13.6) [1352] 53 (7.6) < 0.001
Smoking before pregnancy 13 (14.4) [90] 30 (17.6) [170] 33 (19.0) [174] 0.752 222 (17.4) [1277] 137 (20.4) [670] 0.098
Smoking during pregnancy 6 (6.5) [92] 10 (5.8) [172] 11 (6.3) [176] 0.864 84 (6.5) [1289] 56 (8.2) [682] 0.164
Table 2.  Clinical characteristics of the study participants. Values for continuous variables are median 
(25th/75th percentile), and for categorical variables frequencies (% in parentheses). Number of study participants 
is shown in brackets if different. Comparison of continuous variables was performed with the Mann–Whitney 
U test due to non-normality of the data. Categorical variables were analysed using the chi2 test or the Fisher’s 
exact test if number of observations in any cell was < 5. PE = pre-eclampsia; BMI = body mass index.
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with pre-eclampsia was first tested in the Sequenom genotyped FINNPEC case-control sample set. Three variants 
deviated from HWE in the FINNPEC controls and were omitted. In the association analysis, one of the genotyped 
variants was nominally associated with pre-eclampsia (rs79744308 in NRTN; p-value = 0.0314, OR (95% CI) = 0.69 
(0.48–0.97)), but the variant did not pass differential missingness test between the cases and controls. None of the 
association tests reached genome-wide significance. Full results are shown in Supplementary Table S4.
Association analysis in the combined FINNPEC-SISu data set. In order to increase statistical power, 
we merged the FINNPEC data with the Finnish SISu (3.0) data, and tested association of the genotyped variants 
with pre-eclampsia in this combined data set. Three of the variants deviated from HWE in the controls in these 
data, and were excluded from the analysis. Furthermore, the X chromosomal variants were excluded as the SISu 
data contain both males and females. In the association analysis in the merged data, we detected nominal associ-
ation of four variants (Table 3). None of them, however, reached genome-wide significance. Full results from this 
analysis are presented in Supplementary Table S4. Comparison of MAFs between different sample subsets for the 
28 variants genotyped in the second Sequenom genotyping is shown in Supplementary Table S5.
Figure 1. The main filtering strategy for the variants identified in the exome sequencing. The variants that 
passed quality criteria and were found in at least two pre-eclampsia pools were filtered for function. To further 
narrow down the number of variants, pooled exome sequencing data from Swedish scoliosis patients as well 
as the 1000 Genomes European data and the Finnish Sequencing Initiative Suomi (SISu) data were utilised in 
the filtering. Variants remaining after each filtering step are indicated in red boxes. Based on the main filtering 
steps, 52 variants were selected. Furthermore, seven variants were selected based on additional filtering 
strategies. *The reference data used: the pooled exome sequencing data from Swedish scoliosis patients; the 1000 
Genomes European data (APR 2012); and the Finnish SISU data (2014). †Fuentes Fajardo et al.34 and Ju et al.35. 
‡The missense, nonsense and splice site variants with the 1000 Genomes European reference allele frequency 
≤ 0.05, pre-eclampsia_refAllele/SISu and pre-eclampsia_refAllele/scoliosis_refAllele ≥ 1.5, reference allele 
present in ≤ 2 scoliosis pools and in over two pre-eclampsia pools. $A nonsense variant present in only one pre-
eclampsia pool and a variant located in the previously identified linkage peak region were selected outside the 
main filtering strategy. 1 KG = The 1000 Genomes Project; MAF = minor allele frequency; PE = pre-eclampsia, 
SCO = the pooled exome sequencing data from Swedish scoliosis patients.
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The variant rs6025, which is located in the F5 gene and has previously been connected to pre-eclampsia15–17, 
was not associated with pre-eclampsia in our study in either of the analyses.
Quantitative traits association analysis. Assuming an additive model of genetic inheritance, we inves-
tigated the association between the genotyped SNPs and quantitative clinical characteristics of pre-eclampsia 
(Supplementary Table S6). Among the SNPs nominally associated with pre-eclampsia (Table 3), rs3803339/G 
allele in TP53BP1 showed nominal association (p-value = 0.026) with the highest systolic blood pressure, and 
rs61747120/T in ZFR2 with proteinuria (p-value = 0.039), both in the pre-eclamptic women. In addition to those 
two SNPs, there were several other variants associated with the highest systolic or diastolic blood pressure, relative 
birth weight of the baby or proteinuria in the pre-eclamptic patients, the non-pre-eclamptic controls or the whole 
case-control sample set (Supplementary Table S6). Rs2291516 in RGL3 was associated with both proteinuria 
(p-value = 0.001) and relative birth weight of the baby (p-value = 7.3 × 10−4). However, none of the SNPs were 
associated with the quantitative traits at the genome-wide significance level.
Discussion
In this first attempt to screen exome-wide for low-frequency, moderate or large-effect risk variants for 
pre-eclampsia in a Finnish founder population, we did not find any genome-wide significantly associated risk 
variants. Whereas many complex diseases such as type 2 diabetes or cardiovascular diseases often have onset 
at midlife or later, pre-eclampsia affects women at their reproductive years, or if the phenotype of offspring is 
considered, already during the fetal period. Consequently, the disease decreases reproductive success, and there 
is a reason to hypothesise that pre-eclampsia risk variants are under negative evolutionary selection, which 
would keep their population frequencies low. A couple of GWA studies have assessed the role of common varia-
tion in pre-eclampsia susceptibility18,19, but low-frequency variation has not previously been studied exome- or 
genome-wide. A founder population such as Finland, which has gone through relatively recent bottlenecks and is 
enriched for low-frequency loss-of-function mutations24, should be an ideal study population for this screening.
The DNA samples were exome sequenced in pools of ten in order to maximise the number of sequenced 
samples while maintaining the sequencing costs low. With this strategy we were able to perform cost-effective 
exome-wide screen for pre-eclampsia risk variants, but the approach also has several limitations, such as missing 
information on individual genotypes and on exact MAF of each variant in the study sample. We were able to esti-
mate MAFs from the pooled exome-sequenced samples fairly accurately: correlation coefficient between our esti-
mates and the 1000 Genomes European data was 0.972 when the sequencing depth was at least 30x per pool. We 
however acknowledge that variants with biased MAF estimates were prone to be selected for the Sequenom gen-
otyping, whereas some truly enriched variants could have been missed. In the association analysis we utilized the 
large SISu data as a population specific reference to increase statistical power of the analysis. Both the FINNPEC 
data and the data sets contributing to the SISu project have been collected to represent the Finnish population. 
However, population substructure within Finland39,40 could cause bias especially when studying low-frequency 
variants. For some of the variants allele frequencies differ between the FINNPEC and SISu controls indicating 
potential for subtle population stratification. We were unable to test the existence of population stratification due 
to the limited number of SNPs genotyped in our data. Another potential source of bias is that the data sets have 
been genotyped with different methods.
There are several possible explanations for not identifying pre-eclampsia risk variants in this study. Our 
screening did not cover non-coding regions, and also structural variation was omitted from the analysis. 
Furthermore, variants in low-coverage regions could have been missed. At the time of the exome sequencing data 
analysis robust variant callers with ploidy setting were not available. Utilizing a caller assuming a diploid genome 
might have caused us to miss some candidate variants. Some risk variants may have been lost due to choices made 
in the filtering. As shown previously, variant annotations are much dependent on a transcript set and annotation 
software utilized, and often there are several plausible annotations for a single variant41. Variants with incorrect or 
alternative annotations may have been unintentionally filtered out. Genetic risk for pre-eclampsia might be het-
erogeneous even in an isolated population, and a larger sample size might have been needed to find predisposing 
variants. As the sample size in the exome sequencing was modest, false negative results can occur. Furthermore, 
our study was underpowered to detect rare variants or variants with small effect sizes. Especially in the case of 
rare pre-eclampsia risk variants, gene-based testing methods might be needed to reveal disease association. The 
approach taken in this study was nevertheless justified. In another study we and co-workers used identical design 
Gene rs number A2
MAF 
PE case
MAF non-
PE ctrl
MAF 
SISu
MAF SISu + 
non-PE ctrl P* OR (CI 95%)*
TP53BP1 rs3803339 G 0.046 0.038 0.035 0.035 0.0058 1.33 (1.09–0.63)
ZFR2 rs61747120 T 0.066 0.067 0.054 0.055 0.0237 1.22 (1.03–1.44)
ANO9 rs113926353 G 0.036 0.038 0.045 0.044 0.0477 0.80 (0.64–1.00)
TMTC1 rs142394560 A 0.040 0.031 0.032 0.032 0.0477 1.25 (1.00–1.57)
Table 3.  The SNPs nominally associated with pre-eclampsia in the analysis in the combined FINNPEC and 
SISu data set. * Pre-eclamptic cases compared to the combined control data (the non-pre-eclamptic FINNPEC 
controls + the SISu (3.0) data, in which information on pre-eclampsia was not available). A2 = minor allele; 
MAF = minor allele frequency; PE = pre-eclampsia; SISu = Sequencing Initiative Suomi; OR = odds ratio; 
CI = confidence interval.
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to reveal genetic variants associated with morbid obesity, and identified a low-frequency variant that showed 
strong association with BMI42, a complex trait that is similarly to pre-eclampsia affected by multiple genetic and 
environmental factors.
Although we could not detect any robust risk variant for pre-eclampsia in this study, we mention here five 
missense variants nominally associated either with the disease phenotype (rs3803339 in TP53BP1, rs61747120 
in ZFR2, rs113926353 in ANO9, and rs142394560 in TMTC1), or with proteinuria and relative birth weight 
of the baby in the pre-eclamptic cases (rs2291516 in RGL3). These variants or genes have not previously been 
linked to pre-eclampsia or any other pregnancy disorders. TP53BP1 encodes a protein involved in DNA damage 
response and cell cycle regulation43. Of interest, variants in TP53BP1 have shown a suggestive association with 
blood pressure44. ZFR2 is a zinc finger RNA binding protein with an unknown function. ANO9 belongs to a fam-
ily of calcium-dependent chloride channels, and might suppress baseline chloride conductance45,46, and TMTC1 
is an endoplasmic reticulum protein involved in calcium homeostasis47. RGL3, which interacts with Rap-family 
G-proteins48, has been shown to affect cell growth and morphology48,49. TP53BP1, TMTC1 and RGL348 are 
expressed in a wide range of tissues, ANO9 most abundantly in skin and digestive tract and ZFR2 in adrenal 
gland, cerebral cortex and testis (http://www.proteinatlas.org/). A larger sample size would have been needed to 
state anything conclusive about the role of the variants in these genes in the risk of pre-eclampsia.
Rs6025 located in the F5 gene has been associated with pre-eclampsia in tens of candidate gene studies (sum-
marized in meta-analyses15–17), and was therefore included as an additional variant in the Sequenom panel. F5 
encodes the Factor V protein, a central component in the coagulation pathway. The amino acid change produced 
by rs6025 prevents inactivation of Factor V, which increases tendency to thrombosis50. To the best of our knowl-
edge this is one of the largest original studies to investigate connection between rs6025 and pre-eclampsia. In 
contrast to many previous studies, our study does not provide support for the association of this variant with 
pre-eclampsia.
Along with two published GWA studies, this study is one of the firsts to screen for pre-eclampsia risk var-
iants exome- or genome-wide. In future studies, a hypothesis-free design with larger sample sizes is required, 
as shown for many other complex phenotypes. One of the features of pre-eclampsia is the involvement of two 
individuals: a mother and a child. Therefore, the genetic information of children should be included in studies on 
pre-eclampsia, and interaction between fetal and maternal genotypes should be studied more comprehensively. 
The multinational InterPregGen consortium has addressed the need for larger sample sizes and for studying 
maternal and fetal genotypic interaction by GWAS genotyping 7600 pre-eclamptic mothers, 4000 pre-eclamptic 
infants and 46000 control women with the aim of identifying genetic risk factors for pre-eclampsia51. The 
FINNPEC cohort is involved as a replication cohort in this biggest effort in genetics of pre-eclampsia to date. 
In parallel with case-control studies on sporadic pre-eclampsia, studies in pre-eclampsia families may help to 
identify genes and pathways involved in the disease susceptibility. We have taken this approach and are currently 
screening for risk variants in the Finnish pre-eclampsia families with next-generation sequencing methods.
In this first exome-wide screening for pre-eclampsia risk variants we did not find any variant that would have 
been robustly associated with the disease phenotype. We conclude that even in a population isolate like Finland, 
the genetic risk for pre-eclampsia is likely complex and heterogeneous, and genome-wide approaches with larger 
sample sizes will be necessary to detect risk factors.
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